Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies
Open Access
- 21 February 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 801733
Abstract
Endometrial cancer (EC) is the sixth most prevalent type of cancer among women. Kinases, enzymes mediating the transfer of adenosine triphosphate (ATP) in several signaling pathways, play a significant role in carcinogenesis and cancer cells’ survival and proliferation. Cyclin-dependent kinases (CDKs) are involved in EC pathogenesis; therefore, CDK inhibitors (CDKin) have a noteworthy therapeutic potential in this type of cancer, particularly in EC type 1. Natural compounds have been used for decades in the treatment of cancer serving as a source of anticancer bioactive molecules. Many phenolic and non-phenolic natural compounds covering flavonoids, stilbenoids, coumarins, biphenyl compounds, alkaloids, glycosides, terpenes, and terpenoids have shown moderate to high effectiveness against CDKin-mediated carcinogenic signaling pathways (PI3K, ERK1/2, Akt, ATM, mTOR, TP53). Pharmaceutical regimens based on two natural compounds, trabectedin and ixabepilone, have been investigated in humans showing short and midterm efficacy as second-line treatments in phase II clinical trials. The purpose of this review is twofold: the authors first provide an overview of the involvement of kinases and kinase inhibitors in the pathogenesis and treatment of EC and then discuss the existing evidence about natural products’ derived kinase inhibitors in the management of the disease and outline relevant future research.Keywords
Funding Information
- National Natural Science Foundation of China
- West China Hospital, Sichuan University
This publication has 143 references indexed in Scilit:
- Endometrial carcinoma: molecular alterations involved in tumor development and progressionOncogene, 2012
- Differential WNT Activity in Colorectal Cancer Confers Limited Tumorigenic Potential and Is Regulated by MAPK SignalingCancer Research, 2012
- Challenges in Development of Nanoparticle-Based TherapeuticsThe AAPS Journal, 2012
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological FeaturesPLOS ONE, 2012
- Cadherins, catenins and cell cycle regulators: Impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trialGynecologic Oncology, 2011
- Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive AgentsCancers, 2011
- Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?Obstetrics and Gynecology International, 2010
- Genetics of Endometrial CancersObstetrics and Gynecology International, 2010
- Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-PJournal of Clinical Oncology, 2009
- Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1Gynecologic Oncology, 2009